Unfortunately, a major hurdle that has significantly limited PACAP therapeutic use in T2D-related injuries depends on the rapid hydrolysis of the peptide occurring when injected systemically. The gene discussed is ADCYAP1; the disease is type 2 diabetes mellitus.